Risk modeling: Applying evidence-based risk assessment in oncology nursing practice

Oncology Nursing Forum

Volumn 32, Issue 1, 2005, Pages 49-56

  Ropka, Mary E ^a,b   Padilla, Geraldine ^c   Gillespie, Theresa W ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; EPIDEMIOLOGY; HUMAN; NURSING CARE; ONCOLOGY NURSING; RISK ASSESSMENT; THEORETICAL MODEL;

COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC STUDIES; HUMANS; MODELS, THEORETICAL; NURSING CARE; ONCOLOGIC NURSING; RISK ASSESSMENT;

EID: 33645237348     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.49-56     Document Type: Article

References (48)

1. Altman, D.G., & Lyman, G.H. (1998). Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Research and Treatment, 52, 289-303.
2. Anderson, K.M., Odell, P.M., Wilson, P.W., & Kannel, W.B. (1991). Cardiovascular disease risk profiles. American Heart Journal, 121(1, Pt. 2), 293-298.
3. Balducci, L., & Yates, J. (2000). General guidelines for the management of older patients with cancer. Oncology, 14, 221-227.
4. Bodey, G.P., Buckley, M., Sathe, Y.S., & Freireich, E.J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328-340.
5. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906.
6. Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205-1211.
7. Caggiano, V., Stolshek, B., Delgado, D., & Carter, B. (2001). First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL) patients on standard dose CHOP therapy [Abstract 1810]. Blood, 98, 431a.
8. Claus, E.B. (2000). Risk models in genetic epidemiology. Statistical Methods in Medical Research, 9, 589-601.
9. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine, 325, 164-170.
10. Di Blasio, C.J., Rhee, A.C., Cho, D., Scardino, P.T., & Kattan, M.W. (2003). Predicting clinical end points: Treatment nomograms in prostate cancer. Seminars in Oncology, 30, 567-586.
11. Domchek, S.M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., & Weber, B.L. (2003). Application of breast cancer risk prediction models in clinical practice. Journal of Clinical Oncology, 21, 593-601.
12. Eddy, D.M. (1990). The challenge. JAMA, 263, 287-290.
13. Euhus, D.M. (2001). Understanding mathematical models for breast cancer risk assessment and counseling. Breast Journal, 7, 224-232.
14. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. Journal of the National Cancer Institute, 90, 1371-1388.
15. Fletcher, R.H., Fletcher S.W., & Wagner, E.H. (1996). Clinical epidemiology: The essentials (3rd ed.). Baltimore: Williams and Wilkins.
16. Freifeld, A., Marchigiani, D., Walsh, T., Chanock, S., Lewis, L., Hiemenz, J., et al. ( 1999). A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine, 341, 305-311.
17. Gail, M.H., Costantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., et al. (1999). Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute, 91, 1829-1846.
18. Gomez, H., Hidalgo, M., Casanova, L., Colomer, R., Pen, D.L., Otero, J., et al. (1998). Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. Journal of Clinical Oncology, 16, 2065-2069.
19. Intragumtornchai, T., Sutheesophon, J., Sutcharitchan, P., & Swasdikul, D. (2000). A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leukemia and Lymphoma, 37, 351-360.
20. Jackson, R. (2000). Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ, 320, 709-710.
21. Kattan, M.W., Eastham, J.A., Stapleton, A.M., Wheeler, T.M., & Scardino, P.T. (1998). A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. Journal of the National Cancer Institute, 90, 166-771.
22. Kattan, M.W., Potters, L., Blasko, J.C., Beyer, D.C., Fearn, P., Cavanagh, W., et al. (2001). Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology, 58, 393-399.
23. Kattan, M.W., Wheeler, T.M., & Scardino, P.T. (1999). Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. Journal of Clinical Oncology, 17, 1499-1507.
24. Kattan, M.W., Zelefsky, M.J., Kupelian, P.A., Scardino, P.T., Fuks, Z., & Leibel, S.A. (2000). Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. Journal of Clinical Oncology, 18, 3352-3359.
25. Kern, W.V., Cometta, A., De Bock, R., Langenaeken, J., Paesmans, M., & Gaya, H. (1999). Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine, 341, 312-318.
26. Klastersky, J., Paesmans, M., Rubenstein, E.B., Boyer, M., Elting, L., Feld, R., et al. (2000). The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying lowrisk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
27. Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
28. Lyman, G.H., & Delgado, D.J. (2002). Risk and timing of hospitalization for febrile neutropenia among patients receiving CHOP-like regimens for intermediate grade non-Hodgkin's lymphoma [Abstract 3085]. Blood, 100, 780a.
29. Lyman, G.H., Lyman, C.H., & Agboola, O. (2001). Risk models for the prediction of chemotherapy-induced neutropenia. Neutropenia in Oncology, 1, 2-7.
30. Lyman, G.H., Morrison, V.A., Dale, D.C., Crawford, J., Delgado, D.J., Fridman. M., et al. (2003). Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leukemia and Lymphoma, 44, 2069-2076.
31. Maxwell, C., Winkler, L., & Lottenberg, M. (2002, April). Nurse-driven neutropenia management guidelines: Improving patient outcomes through evidence-based practice. Presentation at the Oncology Nursing Society 27th Annual Congress, Washington, DC.
32. Meza, L., Baselga, J., Holmes, F.A., Liang, B., & Breddy, J. (2002). Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy [Abstract 2840], Proceedings of the American Society of Clinical Oncology, 21, 255b.
33. Michelson, J.L., Bergen, S., Cichetti, E., Doherty, E., Emens, C., Shedlock, K., et al. (2002, April). Using a neutropenia management protocol to achieve dose intensity for optimal outcome of chemotherapy. Presentation at the Oncology Nursing Society 27th Annual Congress, Washington, DC.
34. Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., et al. (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology, 18, 3558-3585.
35. Paesmans, M. (2000). Risk factors assessment in febrile neutropenia. International Journal of Antimicrobial Agents, 16, 107-111.
36. Rivera, E., Erder, M.H., Fridman, M., Brannan, C., Frye, D., & Hortobagyi, G.H. (2001). Delivering full planned dose on time (PDOT) chemotherapy (CT) while lowering the incidence of febrile neutropenia (FN) hospitalizations: Initial results from a prospective study (N = 528) providing rilgrastim support to high risk breast cancer patients (BCP) [Abstract 3]. Breast Cancer Research and Treatment, 69, 209.
37. Rolston, K.V. (2000). Prediction of neutropenia. International Journal of Antimicrobial Agents, 16, 113-115.
38. Ropka, M.E., & Spencer-Cisek, P. (2001). PRISM: Priority Symptom Management Project phase I: Assessment. Oncology Nursing Forum, 28, 1585-1594.
39. Sackett, D.L., Rosenberg, W.M., Gray, J.A., Haynes, R.B., & Richardson, W.S. (1996). Evidence based medicine: What it is and what it isn't. BMJ, 312, 71-72.
40. Silber, J.H., Fridman, M., DiPaola, R.S., Erder, M.H., Pauly, M.V., & Fox, K.R. (1998). First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. Journal of Clinical Oncology, 16, 2392-2400.
41. Silber, J.H., Fridman, M., Shpilsky, A., Even-Shoshan, O., Smink, D.S., Jayaraman, J., et al. (1998). Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. Journal of Clinical Oncology, 16, 2435-2444.
42. Sokolowska, J., & Pohorille, A. (2000). Models of risk and choice: Challenge or danger. Acta Psychologica, 104, 339-369.
43. Talcott, J.A., Finberg, R., Mayer, R.J., & Goldman, L. (1988). The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Archives of Internal Medicine, 148, 2561-2568.
44. Talcott, J.A., Siegel, R.D., Finberg, R., & Goldman, L. (1992). Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. Journal of Clinical Oncology, 10, 316-322.
45. Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer, 29A, 319-324.
46. Voog, E., Bienvenu, J., Warzocha, K., Moullet, I., Dumontet, C., Thieblemont, C., et al. (2000). Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: Role of the tumor necrosis factor ligand-receptor system. Journal of Clinical Oncology, 18, 325-331.
47. White, N., & Keehne-Miron, J. (2002, April). Assessing clinical outcomes in breast cancer patients in a community-based cancer center. Presentation at the Oncology Nursing Society 27th Annual Congress, Washington, DC.
48. Wilson-Royalty, M., Lawless, G., Palmer, C., & Brown, R. (2001). Predictors for chemotherapy-related severe or febrile neutropenia: A review of the clinical literature. Journal of Oncology Pharmacy Practice, 7, 141-147.